Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Thursday, August 21, 2008

Biochemical individuality: an article by Dr Michael Murray ND

The phrase "one man's meat is another man's poison" perfectly sums up how an individual could potentially react to drugs or herbs or other external or internally produced metabolites. If someone is sub-normal in a certain detox/activation enzyme, they may react very badly to something supposedly good for them.

Dr Michael Murray ND is one of the most respected natural therapists. In this article, he explains how the likes of drugs should be 'tailor-made' for each individual, because our detoxification/activation enzymes often vary greatly. At the moment drugs are designed as if we will all have the same metabolizing capability. This article is of interest in particular because it focuses on the main family of the 'phase 1'/'nonsynthetic reaction' enzymes, the cytochrome P450 (CYP450) family of enzymes. The flavin mono-oxygenase family (of which there are currently 6 different types known) are another of the phase1/nonsynthetic enzymes, but the CYP450 enzymes are regarded as the heavy duty ones, especially CYP3A4.

More will be written about these enzymes and the other main detoxification enzymes over the weeks, in an effort to help us all learn about them.

cytochrome P450, CYP450, CYP3A4
induction, inhibition, substrate
phase1 (nonsynthetic), phase 2 (synthetic)


One of the major determinants of our nutrigenomic profile is a family of perhaps one hundred enzymes known as the cytochrome P450 enzymes. These enzymes play a critical role in detoxifying drugs, cancer-causing compounds, and hormones. Generally, each enzyme is designed to metabolize certain types of chemicals, but there is also a lot of overlap among the P450 family. This “back-up system” ensures that your liver is usually able to detoxify your body efficiently...

...The activity of and interplay between Phase I and Phase II reactions is probably the single most important factor that determines our biochemical individuality. Differences in the P450 enzymes can explain why some people can smoke without developing lung cancer and why certain individuals are more susceptible to the harmful effects of pesticides and other toxic chemicals...

...The study examined the association between heart attack incidence.1 Unlike other studies looking into this association the researchers also measured the activity of the liver enzyme that detoxifies caffeine - cytochrome P450 1A2 (CYP1A2). When the researchers divided the group according to whether they possessed a form of this enzyme that quickly metabolizes caffeine (CYP1A2*1A) or slowly metabolized caffeine (CYP1A2*1F) suddenly the picture on the impact of caffeine intake became very clear. As can be seen from Table 1, those with the rapid caffeine breakdown actually decrease their risk of a heart attack by drinking coffee, while slow caffeine metabolizers actually dramatically increase their risk! Drinking four cups a day of coffee was associated with a 17% decrease risk in fast metabolizers and a 260% increased risk in slow metabolizers...
random links:

nutrigenomics research


Post a Comment